Glaxo SmithKline IPV

Developed for: poliomyelitis
Investigated by: Bill and Melinda Gates Foundation · Centers for Disease Control and Prevention · Fidec Corporation

today NCT01831050 · Ph 4

201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT01831050	May 2013 → Apr 2014	poliomyelitis	Fidec Corporation	Completed	Met primary

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Glaxo SmithKline IPV	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01831050 ↗
Modality	Vaccine	“Inactivated poliovirus vaccine is produced by Glaxo SmithKline” NCT01831050 ↗